These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 37921598

  • 1. Cisplatin-induced PANDAR-Chemo-EVs contribute to a more aggressive and chemoresistant ovarian cancer phenotype through the SRSF9-SIRT4/SIRT6 axis.
    Wang H, Li Y, Wang Y, Shang X, Yan Z, Li S, Bao W.
    J Gynecol Oncol; 2024 Mar; 35(2):e13. PubMed ID: 37921598
    [Abstract] [Full Text] [Related]

  • 2. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.
    Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, Gatza ML, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G.
    EBioMedicine; 2018 Dec; 38():100-112. PubMed ID: 30487062
    [Abstract] [Full Text] [Related]

  • 3. EGCG targeting STAT3 transcriptionally represses PLXNC1 to inhibit M2 polarization mediated by gastric cancer cell-derived exosomal miR-92b-5p.
    Yi J, Ye Z, Xu H, Zhang H, Cao H, Li X, Wang T, Dong C, Du Y, Dong S, Zhou W.
    Phytomedicine; 2024 Dec; 135():156137. PubMed ID: 39566403
    [Abstract] [Full Text] [Related]

  • 4. A positive feedback loop of SRSF9/USP22/ZEB1 promotes the progression of ovarian cancer.
    Wang J, Hu M, Min J, Li X.
    Cancer Biol Ther; 2024 Dec 31; 25(1):2427415. PubMed ID: 39530604
    [Abstract] [Full Text] [Related]

  • 5. Cepharanthine sensitizes gastric cancer cells to chemotherapy by targeting TRIB3-FOXO3-FOXM1 axis to inhibit autophagy.
    Lu YY, Fang YY, Wang SS, Guo J, Song JL, Zhu L, Lin ZK, Wang R, Zhang SY, Qiu WS, Qi WW.
    Phytomedicine; 2024 Dec 31; 135():156161. PubMed ID: 39454374
    [Abstract] [Full Text] [Related]

  • 6. Salidroside overcomes cisplatin resistance in ovarian cancer via the inhibition of CRNDE-mediated autophagy.
    Yu G, Nanding A.
    Mol Cell Biochem; 2024 Dec 05. PubMed ID: 39636431
    [Abstract] [Full Text] [Related]

  • 7. Anti-neoplastic effect of heterophyllin B on ovarian cancer via the regulation of NRF2/HO-1 in vitro and in vivo.
    Shi L, Zhang X, Mao L, Zhang Y.
    Tissue Cell; 2024 Dec 05; 91():102566. PubMed ID: 39341007
    [Abstract] [Full Text] [Related]

  • 8. LCP1 promotes ovarian cancer cell resistance to olaparib by activating the JAK2/STAT3 signalling pathway.
    Gai M, Zhao L, Li H, Jin G, Li W, Wang F, Liu M.
    Cancer Biol Ther; 2024 Dec 31; 25(1):2432117. PubMed ID: 39588922
    [Abstract] [Full Text] [Related]

  • 9. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A, Hiu S, Kunonga PT, Gajjar K, Craig D, Vale L, Winter-Roach BA, Elattar A, Naik R.
    Cochrane Database Syst Rev; 2022 Sep 26; 9(9):CD015048. PubMed ID: 36161421
    [Abstract] [Full Text] [Related]

  • 10. Non-cytotoxic levels of resveratrol enhance the anticancer effects of cisplatin by increasing the methyltransferase activity of CARM1 in human cancer cells.
    Zhao XY, Zhong QH, Tan HW, Yan R, Wang XY, Cai NL, Ji YC, Lau ATY, Xu YM.
    Phytomedicine; 2024 Dec 26; 135():156127. PubMed ID: 39476485
    [Abstract] [Full Text] [Related]

  • 11. Effects of Curcumin and Its Analogue Desmethoxycurcumin on miR-133b and Its Target Gene GSTP-1 in Cisplatin-resistant Ovarian Cancer Cells.
    Ülker EB, Aktaş EÇ, Seyhan MF, Isbir T, Billur D, Timirci-Kahraman Ö.
    Anticancer Res; 2024 Dec 26; 44(12):5351-5359. PubMed ID: 39626913
    [Abstract] [Full Text] [Related]

  • 12. BRIP1 Induced Ferroptosis to Inhibit Glioma Cells and was Associated with Increased Oxidative Stress.
    Chen C, Wu ZH, Lu XJ, Shi JL.
    Discov Med; 2024 Nov 26; 36(190):2264-2273. PubMed ID: 39600281
    [Abstract] [Full Text] [Related]

  • 13.
    Kirtsoglou E, Simpson B, Salisbury L, Baraitser L.
    ; 2020 Nov 26. PubMed ID: 36137063
    [Abstract] [Full Text] [Related]

  • 14. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC, Chen CW, Yen HK, Lin YP, Lai CY, Wang JL, Groot OQ, Janssen SJ, Schwab JH, Hsu FM, Lin WH.
    Clin Orthop Relat Res; 2024 Dec 01; 482(12):2193-2208. PubMed ID: 39051924
    [Abstract] [Full Text] [Related]

  • 15. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J, Gaudet LA, Saba S, Vandermeer B, Ashiq AR, Wingert A, Hartling L.
    Syst Rev; 2024 Nov 26; 13(1):289. PubMed ID: 39593159
    [Abstract] [Full Text] [Related]

  • 16. Icariin promoted ferroptosis by activating mitochondrial dysfunction to inhibit colorectal cancer and synergistically enhanced the efficacy of PD-1 inhibitors.
    Haoyue W, Kexiang S, Shan TW, Jiamin G, Luyun Y, Junkai W, Wanli D.
    Phytomedicine; 2024 Nov 23; 136():156224. PubMed ID: 39642461
    [Abstract] [Full Text] [Related]

  • 17. LMAN2 Promotes Breast Cancer Tumorigenesis and Drug Resistance by Interacting With MAPK9 via Activation of the MAPK Pathway.
    Feng C, Li P, Liu P, Wang B, Li J, Liu P.
    Cancer Med; 2024 Dec 23; 13(23):e70448. PubMed ID: 39618331
    [Abstract] [Full Text] [Related]

  • 18. The oncogene Gankyrin is expressed in testicular cancer and contributes to cisplatin sensitivity in embryonal carcinoma cells.
    Camacho-Moll ME, Macdonald J, Looijenga LHJ, Rimmer MP, Donat R, Marwick JA, Shukla CJ, Carragher N, Jørgensen A, Mitchell RT.
    BMC Cancer; 2019 Nov 19; 19(1):1124. PubMed ID: 31744479
    [Abstract] [Full Text] [Related]

  • 19. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
    Morgan RD, McNeish IA, Cook AD, James EC, Lord R, Dark G, Glasspool RM, Krell J, Parkinson C, Poole CJ, Hall M, Gallardo-Rincón D, Lockley M, Essapen S, Summers J, Anand A, Zachariah A, Williams S, Jones R, Scatchard K, Walther A, Kim JW, Sundar S, Jayson GC, Ledermann JA, Clamp AR.
    Lancet Oncol; 2021 Feb 19; 22(2):277-288. PubMed ID: 33357510
    [Abstract] [Full Text] [Related]

  • 20. Transcription Factor E2F8 Activates PDK1-Mediated DNA Damage Repair to Enhance Cisplatin Resistance in Lung Adenocarcinoma.
    Li H, Sun J, Hu H, Wang Y.
    Pharmacology; 2024 Feb 19; 109(6):341-356. PubMed ID: 38810606
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.